Canada · Delayed Price · Currency is CAD BioRem Statistics
Total Valuation
BioRem has a market cap or net worth of CAD 61.14 million. The enterprise value is 56.44 million.
| Market Cap | 61.14M |
| Enterprise Value | 56.44M |
Important Dates
The next estimated earnings date is Tuesday, August 25, 2026.
| Earnings Date | Aug 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRem has 16.22 million shares outstanding. The number of shares has decreased by -1.13% in one year.
| Current Share Class | 16.22M |
| Shares Outstanding | 16.22M |
| Shares Change (YoY) | -1.13% |
| Shares Change (QoQ) | +2.72% |
| Owned by Insiders (%) | 2.54% |
| Owned by Institutions (%) | n/a |
| Float | 15.80M |
Valuation Ratios
The trailing PE ratio is 11.20 and the forward PE ratio is 9.79.
| PE Ratio | 11.20 |
| Forward PE | 9.79 |
| PS Ratio | 1.21 |
| PB Ratio | 3.48 |
| P/TBV Ratio | 3.48 |
| P/FCF Ratio | 6,315.93 |
| P/OCF Ratio | 186.15 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.42, with an EV/FCF ratio of 5,830.93.
| EV / Earnings | 9.08 |
| EV / Sales | 1.11 |
| EV / EBITDA | 6.42 |
| EV / EBIT | 6.74 |
| EV / FCF | 5,830.93 |
Financial Position
The company has a current ratio of 2.04, with a Debt / Equity ratio of 0.14.
| Current Ratio | 2.04 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | 257.52 |
| Interest Coverage | 56.74 |
Financial Efficiency
Return on equity (ROE) is 43.57% and return on invested capital (ROIC) is 60.28%.
| Return on Equity (ROE) | 43.57% |
| Return on Assets (ROA) | 16.58% |
| Return on Invested Capital (ROIC) | 60.28% |
| Return on Capital Employed (ROCE) | 43.24% |
| Weighted Average Cost of Capital (WACC) | 8.74% |
| Revenue Per Employee | 1.49M |
| Profits Per Employee | 182,829 |
| Employee Count | 34 |
| Asset Turnover | 1.62 |
| Inventory Turnover | 17.95 |
Taxes
In the past 12 months, BioRem has paid 2.02 million in taxes.
| Income Tax | 2.02M |
| Effective Tax Rate | 24.49% |
Stock Price Statistics
The stock price has increased by +86.96% in the last 52 weeks. The beta is 0.85, so BioRem's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +86.96% |
| 50-Day Moving Average | 3.17 |
| 200-Day Moving Average | 2.76 |
| Relative Strength Index (RSI) | 77.10 |
| Average Volume (20 Days) | 32,029 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioRem had revenue of CAD 50.70 million and earned 6.22 million in profits. Earnings per share was 0.34.
| Revenue | 50.70M |
| Gross Profit | 15.41M |
| Operating Income | 8.32M |
| Pretax Income | 8.23M |
| Net Income | 6.22M |
| EBITDA | 8.80M |
| EBIT | 8.38M |
| Earnings Per Share (EPS) | 0.34 |
Balance Sheet
The company has 7.19 million in cash and 2.49 million in debt, with a net cash position of 4.69 million or 0.29 per share.
| Cash & Cash Equivalents | 7.19M |
| Total Debt | 2.49M |
| Net Cash | 4.69M |
| Net Cash Per Share | 0.29 |
| Equity (Book Value) | 17.59M |
| Book Value Per Share | 1.09 |
| Working Capital | 16.84M |
Cash Flow
In the last 12 months, operating cash flow was 328,433 and capital expenditures -318,753, giving a free cash flow of 9,680.
| Operating Cash Flow | 328,433 |
| Capital Expenditures | -318,753 |
| Depreciation & Amortization | 281,653 |
| Net Borrowing | -661,413 |
| Free Cash Flow | 9,680 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 30.40%, with operating and profit margins of 16.41% and 12.26%.
| Gross Margin | 30.40% |
| Operating Margin | 16.41% |
| Pretax Margin | 16.24% |
| Profit Margin | 12.26% |
| EBITDA Margin | 17.35% |
| EBIT Margin | 16.53% |
| FCF Margin | 0.02% |
Dividends & Yields
BioRem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.13% |
| Shareholder Yield | 1.13% |
| Earnings Yield | 10.17% |
| FCF Yield | 0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRem has an Altman Z-Score of 4.41 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.41 |
| Piotroski F-Score | 7 |